FIG. 1.

In vitro oncolytic properties of the dlE102 MAV-1 vector. (A) The EC₅₀s were determined for the pmE301 (wild-type MAV-1), dlE102 (MAV-1 containing a CR2 deletion), and Ad5-E2F vectors in a panel of murine tumor cell lines, including pancreatic cancer (Pan02), colon cancer (CT26), breast cancer (4T1), sarcoma (SAI), and small-cell lung cancer (CMT64) cell lines. Cells were infected in triplicate with a 1-to-5 serial dilution of vector starting at 10,000 PFU/cell in DMEM-1% FBS. Cell viability was assessed after 8 days with a tetrazolium salt-based assay (MTS reagent). The EC₅₀s were determined with the GraphPad Prism software. Killing curves were obtained for pmE301 and dlE102 in (B) murine pancreatic tumor cells (Pan02) and (C) normal murine fibroblasts (SJL MEFs). Cells were infected in triplicate with a 1-to-5 serial dilution of vector starting at 10,000 PFU/cell in DMEM-1% FBS. Cell viability was assessed at 8 days postinfection with a tetrazolium salt-based assay (MTS reagent).